Sorrento Therapeutics, Inc. Form 8-K August 18, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 18, 2014

SORRENTO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of

001-36150 (Commission

33-0344842 IRS Employer

incorporation or organization)

File Number) 6042 Cornerstone Ct. West, Suite B **Identification No.)**

Edgar Filing: Sorrento Therapeutics, Inc. - Form 8-K

San Diego, CA 92121

(Address of principal executive offices)

Registrant s telephone number, including area code: (858) 210-3700

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On August 18, 2014, Sorrento Therapeutics, Inc. (the Company) announced that data published in the *Proceedings of the National Academy of Sciences* (PNAS) demonstrate the potential for the MYC inhibitors that the Company licensed from The Scripps Research Institute.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

99.1 Press Release dated August 18, 2014

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 18, 2014

SORRENTO THERAPEUTICS, INC.

By: /s/ Richard Vincent Name: Richard Vincent

Title: Chief Financial Officer and Secretary